News

Sandoz AG received a positive CHMP opinion for the biosimilar drug EG12014 licensed from EirGenix, Inc.
 2023/09/18

EirGenix's Second Breast Cancer Biosimilar EG1206A Successfully Reaches Phase 1 Clinical Trial Objectives
 2023/05/01
EirGenix rated top 5% Corporate Governance Evaluation at TPEx after second year of the IPO

EirGenix rated top 5% Corporate Governance Evaluation at TPEx after second year of the IPO
 2022/05/04
EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT

EIRGENIX ACHIEVES THE FIFTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
 2022/01/26
MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA

MARKETING AUTHORIZATION APPLICATION (MAA) SUBMITTED FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR TO EMA
 2021/12/21
BIOLOGICS LICENSE APPLICATION (BLA) SUBMITTED TO U.S FDA FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR

BIOLOGICS LICENSE APPLICATION (BLA) SUBMITTED TO U.S FDA FOR EIRGENIX'S TRASTUZUMAB BIOSIMILAR
 2021/12/18
EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM

EG12014'S PHASE III CLINICAL TRIAL INTERIM RESULTS PUBLISHED AT SAN ANTONIO BREAST CANCER SYMPOSIUM
 2021/12/08
EirGenix Completed Its NTD 5.03 Billion Private Placement on the Fifteenth of October

EirGenix Completed Its NTD 5.03 Billion Private Placement on the Fifteenth of October
 2021/10/15
EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT

EIRGENIX ACHIEVES THE FOURTH MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
 2021/07/21
HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION

HONG HAI/FOXCONN FOUNDER TERRY GUO ANNOUNCES INVESTMENT TO ACCELERATE EIRGENIX’S GLOBAL EXPANSION
 2021/04/06
POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX'S PROPOSED TRASTUZUMAB BIOSIMILAR

POSITIVE PHASE III CLINICAL RESULTS FOR EIRGENIX'S PROPOSED TRASTUZUMAB BIOSIMILAR
 2021/03/23
EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について

EIRGENIXは日本市場を拡大するために、日本の会社と長期供給契約の締結について
 2021/03/02
EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL

EIRGENIX COMPLETES NEOADJUVANT TREATMENT AND SURGERY FOR LAST PATIENT IN PHASE III CLINICAL TRIAL
 2020/11/08
VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!

VSTRIP® COVID-19 ANTIGEN RAPID TEST VALIDATED AND APPROVED IN INDIA!
 2020/09/26

Vstrip® COVID-19 Antigen Rapid Test Validated and Approved in India!

EIRGENIX ACHIEVES THE THIRD MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT

EIRGENIX ACHIEVES THE THIRD MILESTONE OF ITS TRASTUZUMAB BIOSIMILAR LICENSING AGREEMENT
 2020/09/11